Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MEN1 | O00255 | 6/20 | 0.39 |
| ▸ | KMT2A | Q03164 | 6/20 | 0.39 |
| ▸ | ALDH1A1 | P00352 | 3/20 | 0.39 |
| ▸ | TP53 | P04637 | 2/20 | 0.39 |
| ▸ | KDM4E | B2RXH2 | 2/20 | 0.39 |
| ▸ | MAPT | P10636 | 2/20 | 0.39 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.39 |
| ▸ | PKM | P14618 | 1/20 | 0.39 |
| ▸ | HPGD | P15428 | 1/20 | 0.39 |
| ▸ | ALOX15 | P16050 | 1/20 | 0.39 |
| ▸ | ALOX12 | P18054 | 1/20 | 0.39 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.39 |
| ▸ | ANPEP | P15144 | 2/20 | 0.33 |
| ▸ | USP2 | O75604 | 1/20 | 0.32 |
| ▸ | CDC25B | P30305 | 1/20 | 0.32 |
| ▸ | RECQL | P46063 | 2/20 | 0.31 |
| ▸ | EDNRA | P25101 | 2/20 | 0.31 |
| ▸ | EDNRB | P24530 | 1/20 | 0.31 |
| ▸ | S100A4 | P26447 | 2/20 | 0.31 |
| ▸ | POLB | P06746 | 2/20 | 0.31 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL30353880 | 0.81 | MEN1 (0.35) | MEN1KMT2AALDH1A1TP53KDM4E | |
| SCHEMBL8069320 | 0.81 | MEN1 (0.35) | MEN1KMT2AALDH1A1TP53KDM4E | |
| SCHEMBL12855365 | 0.76 | ALDH1A1 (0.37) | MEN1KMT2AALDH1A1MAPTCYP3A4 | |
| SCHEMBL12854954 | 0.76 | ALDH1A1 (0.37) | MEN1KMT2AALDH1A1MAPTCYP3A4 | |
| SCHEMBL14682268 | 0.73 | ALDH1A1 (0.34) | MEN1KMT2AALDH1A1KDM4EMAPT | |
| SCHEMBL14616986 | 0.69 | MEN1 (0.55) | MEN1KMT2AALDH1A1TP53KDM4E | |
| SCHEMBL12550536 | 0.69 | MEN1 (0.55) | MEN1KMT2AALDH1A1TP53KDM4E | |
| SCHEMBL14642821 | 0.69 | — | — | |
| SCHEMBL14642927 | 0.67 | — | — | |
| SCHEMBL4601117 | 0.65 | POLB (0.33) | MEN1KMT2APOLBMAOA |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 12 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-9783519-B2 | Palladium/silver co-catalyzed tandem reactions synthesis of phenylacetophenone derivatives by oxabenzonorbornadienes with terminal alkynes and their anti-tumor or anti-cancer activities | HONG KONG BAPTIST UNIVERSITY (HK) | 2017-10-10 | — | — | US | claimed |
| US-20160368890-A1 | PALLADIUM/SILVER CO-CATALYZED TANDEM REACTIONS SYNTHESIS OF PHENYLACETOPHENONE DERIVATIVES BY OXABENZONORBORNADIENES WITH TERMINAL ALKYNES AND THEIR ANTI-TUMOR OR ANTI-CANCER ACTIVITIES | HONG KONG BAPTIST UNIVERSITY (HK) | 2016-12-22 | — | — | US | claimed |
| US-9783519-B2 | Palladium/silver co-catalyzed tandem reactions synthesis of phenylacetophenone derivatives by oxabenzonorbornadienes with terminal alkynes and their anti-tumor or anti-cancer activities | HONG KONG BAPTIST UNIVERSITY (HK) | 2017-10-10 | — | — | US | disclosed |
| US-20160368890-A1 | PALLADIUM/SILVER CO-CATALYZED TANDEM REACTIONS SYNTHESIS OF PHENYLACETOPHENONE DERIVATIVES BY OXABENZONORBORNADIENES WITH TERMINAL ALKYNES AND THEIR ANTI-TUMOR OR ANTI-CANCER ACTIVITIES | HONG KONG BAPTIST UNIVERSITY (HK) | 2016-12-22 | — | — | US | disclosed |
| US-8835658-B2 | Asymmetric synthesis of norcantharidin analougus by alkynylation of oxabenzonorbornadienes and their anticancer activities | HONG KONG BAPTIST UNIVERSITY (HK) | 2014-09-16 | — | — | US | disclosed |
| US-20140187801-A1 | ASYMETRIC SYNTHESIS OF NORCANTHARIDIN ANALOUGUS BY ALKYNYLATION OF OXABENZONORBORNADIENES AND THEIR ANTICANCER ACTIVITIES | YUNNAN UNIVERSITY OF NATIONALITIES (CN) | 2014-07-03 | — | — | US | disclosed |
| US-20110004005-A1 | RHODIUM-PHOSPHORUS COMPLEXES AND THEIR USE IN RING OPENING REACTIONS | LABORATORIOS DEL DR. ESTEVE, S.A. (ES) | 2011-01-06 | — | — | US | disclosed |
| EP-2231570-A1 | RHODIUM-PHOSPHORUS COMPLEXES AND THEIR USE IN RING OPENING REACTIONS | Laboratorios del Dr. Esteve S.A. (ES) | 2010-09-29 | — | — | EP | disclosed |
| EP-2231569-A1 | MICROWAVE-ASSISTED RING OPENING REACTION | Laboratorios del Dr. Esteve S.A. (ES) | 2010-09-29 | — | — | EP | disclosed |
| WO-2009074496-A1 | RHODIUM-PHOSPHORUS COMPLEXES AND THEIR USE IN RING OPENING REACTIONS | LABORATORIOS DEL DR. ESTEVE, S.A. (ES) | 2009-06-18 | — | — | WO | disclosed |
| WO-2009074497-A1 | MICROWAVE-ASSISTED RING OPENING REACTION | LABORATORIOS DEL DR. ESTEVE, S.A. (ES) | 2009-06-18 | — | — | WO | disclosed |
| EP-2070903-A1 | Microwave-assisted ring opening reaction | Laboratorios del Dr. Esteve S.A. (ES) | 2009-06-17 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20140187801-A1 | ASYMETRIC SYNTHESIS OF NORCANTHARIDIN ANALOUGUS BY ALKYNYLATION OF OXABENZONORBORNADIENES AND THEIR ANTICANCER ACTIVITIES | ALKBH3, ASPH, ATL3 | MEN1 2374/4885KMT2A 2450/4885ALDH1A1 245/4885 |
| US-20110004005-A1 | RHODIUM-PHOSPHORUS COMPLEXES AND THEIR USE IN RING OPENING REACTIONS | RPIA, PPIP5K2, POLL | MEN1 2845/4885KMT2A 4832/4885ALDH1A1 4540/4885 |
| US-20160368890-A1 | PALLADIUM/SILVER CO-CATALYZED TANDEM REACTIONS SYNTHESIS OF PHENYLACETOPHENONE DERIVATIVES BY OXABENZONORBORNADIENES WITH TERMINAL ALKYNES AND THEIR ANTI-TUMOR OR ANTI-CANCER ACTIVITIES | PDCD1, PDCD4, TYR | MEN1 3664/4885KMT2A 2154/4885ALDH1A1 177/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.